NLRP3 and colitis: Schisandrin B demonstrated anti-inflammatory effects in both in vivo and in vitro colitis models by suppressing the NLRP3 inflammasome and inducing the AMPK/Nrf2 signaling pathway, protecting against ROS-induced mitochondrial damage and alleviating epithelial cell damage via regulation of pyroptosis 478.